| Role of serotonin receptor signaling in cancer cells and anti-tumor immunity S Karmakar, G Lal Theranostics 11 (11), 5296, 2021 | 119 | 2021 |
| Key activating and inhibitory ligands involved in the mobilization of natural killer cells for cancer immunotherapies S Karmakar, P Pal, G Lal ImmunoTargets and Therapy, 387-407, 2021 | 20 | 2021 |
| Th17 cell promotes apoptosis of IL-23R+ neurons in experimental autoimmune encephalomyelitis SA Sonar, HT Meitei, S Karmakar, A Mishra, S Inamdar, N Lenka, G Lal Clinical Immunology 259, 109898, 2024 | 6 | 2024 |
| Role of Serotonergic System in Regulating Brain Tumor-Associated Neuroinflammatory Responses S Karmakar, G Lal Neuroprotection: Method and Protocols, 181-207, 2024 | 3 | 2024 |
| Valproate mediated proteasome dysfunctions induce apoptosis S Kinger, YA Jagtap, AR Dubey, P Kumar, A Choudhary, S Karmakar, ... Advanced Therapeutics 7 (7), 2300421, 2024 | 1 | 2024 |
| Effector and cytolytic function of natural killer cells in anticancer immunity S Karmakar, A Mishra, P Pal, G Lal Journal of Leukocyte Biology 115 (2), 235-252, 2024 | 1 | 2024 |
| Ketorolac disturbs proteasome functions and induces mitochondrial abnormality‐associated apoptosis P Kumar, S Kinger, AR Dubey, YA Jagtap, A Choudhary, S Karmakar, ... IUBMB life 77 (1), e2937, 2025 | | 2025 |
| NOVEL COMBINATION OF SEROTONIN RECEPTOR (5-HTR2B) ANTAGONIST AND AN IMMUNOMODULATOR AND CHEMOTHERAPEUTIC DRUGS FOR INHIBITION OF CANCER G Lal, S Karmakar US Patent App. 18/696,916, 2024 | | 2024 |
| Tachykinin receptor 1 antagonism promotes the Foxp3+ regulatory CD4 T cells and controls gut inflammation and autoimmunity A Mishra, S Karmakar, N Halder, MA Habib, D Kumar, G Lal EUROPEAN JOURNAL OF IMMUNOLOGY 54, 460-460, 2024 | | 2024 |
| Acetaminophen induces mitochondrial apoptosis through proteasome dysfunctions YA Jagtap, P Kumar, AR Dubey, S Kinger, A Choudhary, S Karmakar, ... Life Sciences 349, 122732, 2024 | | 2024 |
| Antagonism of Tachykinin receptor 1 promotes Foxp3+ regulatory CD4 T cells and controls gut mucosal inflammation G Lal, A Mishra, S Karmakar, N Halder, M Habib, D Kumar | | 2024 |
| Cancer immunotherapy 1105: Serotonin receptor 5HTR2B antagonism promotes the efficiency of immune checkpoint blockade therapy of colon cancer. SK Girdhari Lal 18th International Congress of Immunology - IUIS 2023, Cape Town, South …, 2023 | | 2023 |
| Cancer Immunology 844: Antagonizing serotonin receptor 5-HTR2B improves antigen- specific tumor immunity in colon adenocarcinoma GL Surojit Karmakar 18th International Congress of Immunology - IUIS 2023, Cape Town, South …, 2023 | | 2023 |
| Novel combination of serotonin receptor (5-htr2b) antagonist and an immunomodulator and chemotherapeutic drugs for inhibition of cancer GL Surojit Karmakar IN Patent WO2023053142A1, 2023 | | 2023 |
Girdhari LalScientist, National Centre for Cell Science, Pune, IndiaEmail verificata su nccs.res.in